Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience

Experts discuss clinical experience with established and emerging treatment approaches in diffuse large B-cell lymphoma (DLBCL), including R-CHOP and polatuzumab-based regimens, and the factors guiding treatment selection for first-line DLBCL, along with observed outcomes across different patient subgroups.

EP: 1.Advances in DLBCL Management: Long-Term Treatment Outcomes

EP: 2.Long-Term Outcomes and Treatment Guidelines in DLBCL Management

Now Viewing

EP: 3.Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience

EP: 4.DLBCL Subtype Response Patterns: Optimizing Treatment Selection

EP: 5.Disease Progression in DLBCL: Management Strategies and Quality-of-Life Considerations

EP: 6.Treatment Decision-Making in DLBCL: Balancing Efficacy, Safety, and Patient Factors

EP: 7.Long-Term Data and Future Directions in First-Line DLBCL Treatment

Video content above is prompted by the following:

Please share your clinical experience with established and emerging treatment approaches in DLBCL, including R-CHOP and polatuzumab-based regimens.
• When treating first-line DLBCL, what factors guide your selection between various treatment regimens, and what outcomes have you observed across different patient subgroups?

Recent Videos